Free Trial
ASX:IPD

ImpediMed (IPD) Stock Price, News & Analysis

ImpediMed logo

About ImpediMed Stock (ASX:IPD)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
1.62 million shs
Average Volume
N/A
Market Capitalization
$103.31 million
P/E Ratio
N/A
Dividend Yield
3.28%
Price Target
N/A
Consensus Rating
N/A

Company Overview

ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema, and deliver snapshot of fluid status and tissue composition; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia.

Receive IPD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImpediMed and its competitors with MarketBeat's FREE daily newsletter.

IPD Stock News Headlines

When This Happens, You Don’t Wait. You Act.
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
ImpediMed Unaffected by New U.S. Tariffs
See More Headlines

IPD Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that ImpediMed investors own include Bardoc Gold (BDC) and Appen (APX).

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
Current Symbol
ASX:IPD
CIK
N/A
Fax
N/A
Employees
76
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
-102.5
Net Income
-$19.79 million
Net Margins
-191.78%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10.32 million
Price / Cash Flow
1.60
Book Value
A$0.02 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
2,020,000,000
Free Float
N/A
Market Cap
$103.31 million
Optionable
Not Optionable
Beta
2.86
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (ASX:IPD) was last updated on 6/25/2025 by MarketBeat.com Staff
From Our Partners